1Brenner BM. Mackenzie HS. Nephron mass as a risk factor for progression of renal disease[J], Kidney Int, 1997,63 (Suppl) : S124-S127.
2Zoja C, Benigni A, Remuzzi G, et al. Cellular responses to protein overload:key event in renal disease progession[J]. Curr Opin Nephrol Hypertens,2004,13(1):31-37.
4Palatini P,Graniero GR, Canali C, et al. Relationship between albumin excretion rate, ambulatory blood pressure and left ventricular hypertrophy in mild hypertension[J]. J Hypertens, 1995,13(12 Pt 2):1796-1800.
5Chagnac A, Weinstein T, Korzets A, et al. Glomerular hemodynamics in severe obesity [J]. Am J Physiol Renal Physiol, 2000,278(5) :F817-822.
7Weber M. The telmisartan programme of research to show telmisartan end-organ protection programme[J]. J Hyertens, 2003,21(Suppl 6) :S37-S46.
8Benson SC,Pershadsingh HA, Ho CI, et al. Indentification of telmisartan as a unique angiotension Ⅱ receptor antangonist with selective PPAR gamma-modulating activity [ J ].Hypertension, 2004,43 (5) :993-1002.
9de Zeeuw D. Albuminuria, just a marker for cardiovascular disease,or is it more? [J]. J Am Soc Nephrol, 2005,16(7) 1883-1885.
10de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy:lessons from RENAAL[J], Kidney Int, 2004,65(6) :2309-2320.
